Evidence map›Paper›PMID 19141355›Full record

ReviewImmunology and allergy clinics of North America2009

Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis.

Seema S Aceves, Steven J Ackerman

3 registry-linked trialsOpen access · greenAbstract readReview
In one paragraph

Review in Immunology and allergy clinics of North America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01458418 naterminatednot on this mapstarted 2011, after this paper: background citation

A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children

TypeinterventionalSponsorChildren's Mercy Hospital Kansas CityRan2011 to 2015Enrolled4ConditionsEosinophilic EsophagitisArmsMontelukast, placebo, 5 mg Montelukast
NCT03354221 nawithdrawnnot on this mapstarted 2017, after this paper: background citation

A Pilot Study Assessing the Efficacy of Short Duration Six Food Elimination Diet in Eosinophilic Esophagitis (EoE)

TypeinterventionalSponsorMayo ClinicRan2017 to 2019Enrolled0ConditionsEosinophilic EsophagitisArmsCytosponge, Diet, EEsAI Pro, Likert Scoring Scale
NCT06665971 phase4recruitingnot on this mapstarted 2024, after this paper: background citation

Effect of Dupilumab on Esophageal Peristaltic Function in Participants with Eosinophilic Esophagitis

TypeinterventionalSponsorUniversity of California, San DiegoRan2024 to 2026Enrolled30ConditionsEosinophilic Esophagitis (EoE)ArmsDupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Prostaglandin EbioRxiv : the preprint server for biology · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. The Modulated Role ofPathogens (Basel, Switzerland) · 2023
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. IL-36 in chronic inflammation and fibrosis - bridging the gap?The Journal of clinical investigation · 2021
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Seema S AcevesDivision of Allergy and Immunology, Rady Children's Hospital, 3020 Children's Way, MC 5114, San Diego, CA 92123-6791, USA.
Steven J Ackerman
Ashland (United States) · USRady Children's Hospital-San Diego · US

Funding

Novel minimally invasive assessment of gastrointestinal inflammation in food alleR21AI079925 · NIAID · UNIVERSITY OF COLORADO DENVER · PI ACKERMAN, STEVEN JULES, FURUTA, GLENN T · 2008 to 2009
$441k
NIAID NIH HHS R21 AI079925NIAID NIH HHS R21AI079925
6 · The paper itself

Abstract

The clinical and pathologic features of eosinophilic esophagitis (EE) include extensive tissue remodeling. Increasing evidence supports a key role for the eosinophil in multiple aspects of the esophageal remodeling and fibrosis seen in this allergic disease. This article reviews the clinical implications of esophageal remodeling and fibrosis in EE and discusses the possible pathogenic mechanisms inducing and regulating these responses. The focus is specifically on eosinophil and cytokine interactions with the esophageal epithelium, vascular endothelium, resident fibroblasts, and smooth muscle. Current and potential therapeutic interventions are discussed that may impact the development or resolution of chronic esophageal remodeling and fibrosis in EE.

Indexed as

AnimalsCell CommunicationCell MovementCell SurvivalChemotactic Factors, EosinophilEndothelial CellsEosinophiliaEosinophilsEsophagitisFibroblastsFibrosisHumansHypersensitivityInflammationIntestinal MucosaNerve Growth FactorsChemotactic Factors, EosinophilNerve Growth FactorsTransforming Growth Factor beta

Identifiers

PMID19141355
PMCPMC2665721
OpenAlexW2046222341

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.